{"title":"Tirzepatide reduces sleep events in patients with sleep apnea and obesity","authors":"","doi":"10.1002/pu.31214","DOIUrl":null,"url":null,"abstract":"<p>Two Phase 3 trials have found that tirzepatide, a medication used to treat type 2 diabetes, reduced apnea events and body weight in patients with obstructive sleep apnea and obesity. Tirzepatide had comparable safety results to placebo in the two trials.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"4"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31214","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Two Phase 3 trials have found that tirzepatide, a medication used to treat type 2 diabetes, reduced apnea events and body weight in patients with obstructive sleep apnea and obesity. Tirzepatide had comparable safety results to placebo in the two trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
